ATE152914T1 - Verwendung eines thymosins bei der behandlung von hepatitis c - Google Patents

Verwendung eines thymosins bei der behandlung von hepatitis c

Info

Publication number
ATE152914T1
ATE152914T1 AT92919977T AT92919977T ATE152914T1 AT E152914 T1 ATE152914 T1 AT E152914T1 AT 92919977 T AT92919977 T AT 92919977T AT 92919977 T AT92919977 T AT 92919977T AT E152914 T1 ATE152914 T1 AT E152914T1
Authority
AT
Austria
Prior art keywords
thymosin
thymosine
hepatitis
treatment
immune system
Prior art date
Application number
AT92919977T
Other languages
German (de)
English (en)
Inventor
Milton Mutchnick
Paul Chretian
Kenneth E Sherman
Original Assignee
Alpha 1 Biomedicals Inc
Univ Wayne State
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State, Us Army filed Critical Alpha 1 Biomedicals Inc
Application granted granted Critical
Publication of ATE152914T1 publication Critical patent/ATE152914T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2292Thymosin; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Beans For Foods Or Fodder (AREA)
AT92919977T 1991-09-13 1992-09-08 Verwendung eines thymosins bei der behandlung von hepatitis c ATE152914T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954491A 1991-09-13 1991-09-13

Publications (1)

Publication Number Publication Date
ATE152914T1 true ATE152914T1 (de) 1997-05-15

Family

ID=25056052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919977T ATE152914T1 (de) 1991-09-13 1992-09-08 Verwendung eines thymosins bei der behandlung von hepatitis c

Country Status (23)

Country Link
US (3) US6001799A (Direct)
EP (1) EP0603305B1 (Direct)
JP (1) JP3228512B2 (Direct)
KR (1) KR100254082B1 (Direct)
AT (1) ATE152914T1 (Direct)
AU (1) AU667327B2 (Direct)
CA (1) CA2119006C (Direct)
CZ (1) CZ286827B6 (Direct)
DE (1) DE69219782T2 (Direct)
DK (1) DK0603305T3 (Direct)
ES (1) ES2103966T3 (Direct)
FI (1) FI107879B (Direct)
GR (1) GR3024025T3 (Direct)
HK (1) HK1021687A1 (Direct)
HU (1) HU221006B1 (Direct)
MX (1) MX9205240A (Direct)
NO (1) NO941310D0 (Direct)
RO (1) RO111991B1 (Direct)
RU (1) RU2104010C1 (Direct)
SG (1) SG64897A1 (Direct)
TW (1) TW224053B (Direct)
WO (1) WO1993005806A1 (Direct)
ZA (1) ZA926964B (Direct)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (Direct) * 1991-09-13 1994-05-21 Paul B Chretien
SG64892A1 (en) * 1992-02-06 1999-05-25 Sciclone Pharmaceuticals Method for treating hepatitis b carriers with minimal disease
EP0627930A4 (en) * 1992-07-13 1997-08-20 Kenneth E Sherman COMPOSITION AND METHOD FOR TREATING HEPATITIS B.
AU751199B2 (en) * 1992-07-13 2002-08-08 Government Of The United States Of America As Represented By The Secretary Of The Army Composition and method of treating hepatitis B
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
TW249754B (Direct) * 1993-10-26 1995-06-21 Alpha I Biomedicals Inc
CA2175337C (en) * 1993-11-05 2000-06-20 Paul B. Chretien Method and composition for treatment of patients having decompensated liver disease
JP3837769B2 (ja) * 1995-06-12 2006-10-25 大塚製薬株式会社 抗ウイルス剤
US6884411B1 (en) * 1996-02-28 2005-04-26 Unihart Corporation Method of treating viral hepatitis by administration of liquid human α-interferon
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
MXPA02011691A (es) 2000-05-26 2004-05-17 Idenix Cayman Ltd Metodos y composiciones para el tratamiento de flavivirus y pestivirus.
AU2001283536B2 (en) * 2000-08-07 2005-09-01 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin, interferon and ribavirin
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
US6878364B2 (en) * 2000-12-01 2005-04-12 Cornell Research Foundation, Inc. Animal model for flaviviridae infection
RU2211703C2 (ru) * 2001-06-08 2003-09-10 ООО НТЦ "Юпитер-2" Антистрессорное и ноотропное средство с антивирусным и иммуностимулирующим действием
US7138376B2 (en) * 2001-09-28 2006-11-21 Idenix Pharmaceuticals, Inc. Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides
KR20050033518A (ko) * 2001-10-05 2005-04-12 인터뮨, 인크. 간섬유증과 c형 간염바이러스 감염의 치료 방법
DE60224435T2 (de) * 2001-10-26 2009-01-02 Rhode Island Hospital Thymosin-augmentation bei genetischer immunisierung
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
AU2003217402A1 (en) * 2002-02-14 2003-09-04 Pharmasset Inc Modified fluorinated nucleoside analogues
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
DK1523489T3 (da) 2002-06-28 2014-06-16 Idenix Pharmaceuticals Inc Modificerede 2'- og 3'-nukleosidprodrugs til behandling af flaviridae-infektioner
MXPA05005192A (es) 2002-11-15 2005-09-08 Idenix Cayman Ltd Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
WO2004052899A2 (en) 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
JP4149296B2 (ja) * 2003-03-26 2008-09-10 株式会社ルネサステクノロジ 半導体記憶装置
JP4629033B2 (ja) * 2003-03-28 2011-02-09 サイクローン・ファーマシューティカルズ・インコーポレイテッド チモシンα1によるアスペルギルス感染の治療
PT1613340E (pt) * 2003-03-28 2010-08-19 Sciclone Pharmaceuticals Inc Tratamento de infecções por aspergillus com timosina alfa 1
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
ES2351603T3 (es) * 2003-07-25 2011-02-08 Idenix Pharmaceuticals, Inc. Análogos de nucleósidos de purina para el tratamiento de enfermedades causadas por flaviridae incluyendo hepatitis c.
WO2005021007A1 (fr) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention et traitement de l'hepatite virale b
WO2005107742A1 (en) 2004-05-05 2005-11-17 Yale University Novel antiviral helioxanthin analogs
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
SG158136A1 (en) 2004-09-14 2010-01-29 Pharmasset Inc Preparation of 2`-fluoro-2`- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
EP1976382B1 (en) 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
SI2012816T1 (sl) * 2006-05-02 2012-09-28 Sigma Tau Ind Farmaceuti Uporaba timozina 1, samega ali v kombinaciji s PTX3 ali ganciklovirjem, za zdravljenje citomegalovirusne infekcije
ES2288118B1 (es) * 2006-05-10 2008-11-01 Bcn Peptides, S.A. Procedimiento para sintetizar timosinas.
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
EP2349315A4 (en) * 2008-10-08 2012-07-04 Univ Miami LYMPHOCYTE REGULATION AND APPLICATION
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CL2009002207A1 (es) 2008-12-23 2011-02-18 Gilead Pharmasset Llc Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
SI3290428T1 (sl) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tableta, ki obsega kristalinični (S)-izopropil 2-(((S)-(((2R,3R,4R,5R) -5-(2,4-diokso-3,4-dihidropirimidin-1(2H)-il)-4-fluoro-3-hidroksi-4- metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
CN103800293B (zh) * 2012-11-09 2015-10-21 长春海悦药业有限公司 一种含有胸腺法新的药物组合物及其制剂
WO2015030853A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
US5273963A (en) * 1991-03-29 1993-12-28 The George Washington University Compositions and methods for treating small cell and nonsmall cell lung cancers
TW224053B (Direct) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
DE69219782D1 (de) 1997-06-19
ES2103966T3 (es) 1997-10-01
EP0603305B1 (en) 1997-05-14
AU2644792A (en) 1993-04-27
US5849696A (en) 1998-12-15
US20070218033A1 (en) 2007-09-20
RU94022480A (ru) 1996-07-20
JP3228512B2 (ja) 2001-11-12
WO1993005806A1 (en) 1993-04-01
HUT75166A (en) 1997-04-28
RU2104010C1 (ru) 1998-02-10
CA2119006C (en) 2005-08-23
KR100254082B1 (ko) 2000-09-01
US6001799A (en) 1999-12-14
GR3024025T3 (en) 1997-10-31
NO941310L (no) 1994-04-12
EP0603305A1 (en) 1994-06-29
JPH06510998A (ja) 1994-12-08
SG64897A1 (en) 1999-05-25
FI941133A0 (fi) 1994-03-10
HU9400758D0 (en) 1994-06-28
CZ55194A3 (en) 1994-10-19
RO111991B1 (ro) 1997-04-30
FI941133L (fi) 1994-03-10
DE69219782T2 (de) 1997-10-09
CZ286827B6 (cs) 2000-07-12
CA2119006A1 (en) 1993-04-01
AU667327B2 (en) 1996-03-21
MX9205240A (es) 1993-07-01
ZA926964B (en) 1993-04-26
TW224053B (Direct) 1994-05-21
FI107879B (fi) 2001-10-31
HK1021687A1 (en) 2000-06-23
HU221006B1 (hu) 2002-07-29
DK0603305T3 (da) 1997-09-01
NO941310D0 (no) 1994-04-12

Similar Documents

Publication Publication Date Title
ATE152914T1 (de) Verwendung eines thymosins bei der behandlung von hepatitis c
FI962613L (fi) Menetelmä inaktivointikäsittelyn virusinaktivointikapasiteetin määrittämiseksi
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
DE69232565D1 (de) Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
DK0380230T3 (da) Immunogene sammensætninger mod gastrin-peptider
EP0589252A3 (en) Method of inducing fibrillation in implantable devices.
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE3782917D1 (de) Verfahren zum herabsetzen des gehalts an rueckstaendigen aldehyden in implantierbaren bioprosthetischen geweben.
DE69105738D1 (de) System zur frequenzsteuerung eines herzschrittmachers in abhängigkeit von atrioventrikulären intervall.
ATE30326T1 (de) Cyclische pentapeptide mit somatostatin antagonistischer wirksamkeit und verfahren zur behandlung von saeugetieren damit.
DE69327742D1 (de) Holzbehandlungsverfahren
DE68906650D1 (de) Verfahren zur zementierung von plattformbeinen.
SG46620A1 (en) Method and composition foor the treatment of autoimmune hepatitis
EP0325129A3 (en) Disubstituted pyridines
FI941705A0 (fi) Menetelmä viruspatogeenien läpipääsyn estämiseksi
DE69220939D1 (de) Gegengift immunsera
NO910219L (no) Behandling av tre og trebaserte materialer.
DE69030584D1 (de) Verfahren sowie zusammensetzungen zur behandlung mit vitaminmineral
DE68903208D1 (de) Verfahren zur thermischen behandlung von laktoferrin.
DE59001565D1 (de) Verfahren zur verminderung der resteinspritzmenge von einspritzpumpen.
DE69428112D1 (de) Verwendung von thymosin zur behandlung von hepatitis c bei patienten, die auf interferongaben nicht ansprechen
DE59103291D1 (de) Verfahren zur bekämpfung von samen- und/oder bodenbürtigen schaderregern durch saatgutbehandlung.
MY129918A (en) Method for treating hypertension.
DE69214139D1 (de) Verfahren zur behandlung von mit feuchtigkeit enthaltenden feinkohlen
UA10000A (uk) Спосіб лікування гострої недостатності тканинного дихання

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification